

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 29, 2020

Proteostasis Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-37695
(Commission
File Number)

20-8436652
(I.R.S. Employer
Identification No.)

80 Guest Street, Suite 500
Boston, MA
(Address of principal executive offices)

02135
(Zip Code)

Registrant's telephone number, including area code (617) 225-0096
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol</u>	<u>Name of exchange on which registered</u>
Common stock, par value \$0.001 per share	PTI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders

Our virtual annual meeting of shareholders (the “Meeting”) was held on June 29, 2020 exclusively online via live Internet webcast. A quorum was present. At the Meeting, our shareholders elected Meenu Chhabra, Jeffery W. Kelly, Ph.D. and David Arkowitz to serve as Class II directors on our board of directors until the annual meeting of shareholders to be held in 2023. The tabulation of votes with respect to the election of such directors was as follows:

	For	Withheld	Broker Non Vote
Meenu Chhabra	8,660,020	1,695,163	26,377,166
Jeffery W. Kelly, Ph.D.	8,730,909	1,624,274	26,377,166
David Arkowitz	8,702,286	1,652,897	26,377,166

In addition, our shareholders ratified the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. The tabulation of votes with respect to these proposals was as follows:

	For	Against	Abstain
Ratification of the appointment of PricewaterhouseCoopers LLP	36,047,985	508,292	176,072

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 1, 2020

PROTEOSTASIS THERAPEUTICS, INC.

By: /s/ Meenu Chhabra

Meenu Chhabra

President and Chief Executive Officer